SCHEMBL2836294

SCHEMBL2836294

C=CCCCCCCCCCCCCCCCCCCOC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.56
MAPT P10636 3/20 0.56
USP2 O75604 3/20 0.56
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
RECQL P46063 1/20 0.56
ALDH1A1 P00352 5/20 0.54
HPGD P15428 2/20 0.54
LPAR3 Q9UBY5 2/20 0.50
LPAR2 Q9HBW0 1/20 0.50
TSHR P16473 5/20 0.48
ABCC4 O15439 1/20 0.47
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
PTGS2 P35354 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592903 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2837141 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2839053 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL8463541 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2841007 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL585734 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2838417 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL816892 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2837462 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL28416989 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129347-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES California Institute of Technology (US) 2017-02-15 EP claimed
WO-2015157736-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-10-15 WO claimed
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-08 US claimed
EP-2970533-B1 LUBRICANT COMPOSITIONS INCLUDING ALPHA-OLEFIN COPOLYMERS WILMAR TRADING PTE LTD (SG) 2023-07-19 EP disclosed
EP-3488925-B1 RUTHENIUM COMPLEXES CALIFORNIA INST OF TECHN (US) 2022-04-27 EP disclosed
EP-3453748-B1 ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS BIOSYNTHETIC TECHNOLOGIES LLC (US) 2021-11-03 EP disclosed
EP-3904362-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES California Institute of Technology (US) 2021-11-03 EP disclosed
EP-3129347-B1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES CALIFORNIA INST OF TECHN (US) 2021-10-06 EP disclosed
EP-3851442-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES California Institute of Technology (US) 2021-07-21 EP disclosed
CN-105189576-B High viscosity alpha-olefin copolymer compositions and methods of making and using the same 丰益贸易私人有限公司 2021-03-23 CN disclosed
EP-2970532-B1 HIGH-VISCOSITY ALPHA-OLEFIN COPOLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME ELEVANCE RENEWABLE SCIENCES (US) 2020-07-29 EP disclosed
US-8580985-B2 Processes for preparing estolide base oils and oligomeric compounds that include cross metathesis BIOSYNTHETIC TECHNOLOGIES, LLC (US) 2013-11-12 US disclosed
US-8569560-B2 Synthesis of terminal alkenes from internal alkenes via olefin metathesis ELEVANCE RENEWABLE SCIENCES, INC. (US) 2013-10-29 US disclosed
US-8501973-B2 Synthesis of terminal alkenes from internal alkenes via olefin metathesis ELEVANCE RENEWABLE SCIENCES, INC. (US) 2013-08-06 US disclosed
WO-2013095945-A1 PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS BIOSYNTHETIC TECHNOLOGIES, LLC (US) 2013-06-27 WO disclosed
US-20130158277-A1 PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS BIOSYN HOLDINGS, LLC 2013-06-20 US disclosed
US-20130035532-A1 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS Elevance Renewable Sciences. Inc (US) 2013-02-07 US disclosed
US-20100145086-A1 Synthesis of Terminal Alkenes From Internal Alkenes Via Olefin Metathesis ELEVANCE RENEWABLE SCIENCES, INC. 2010-06-10 US disclosed
EP-2076484-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS Elevance Renewable Sciences, Inc. (US) 2009-07-08 EP disclosed
WO-2008046106-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158277-A1 PROCESSES FOR PREPARING ESTOLIDE BASE OILS AND OLIGOMERIC COMPOUNDS THAT INCLUDE CROSS METATHESIS SQLE, ALOX12, ALOX15 CYP3A4 1136/4885MAPT 2801/4885USP2 2898/4885
US-20130035532-A1 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS COASY, SQLE, POR CYP3A4 89/4885MAPT 2992/4885USP2 740/4885
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES DDC, LTC4S, CYCS CYP3A4 31/4885MAPT 4101/4885USP2 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.